Quidel Corporation (QDEL) EPS Estimated At $0.45

January 20, 2018 - By Dolores Ford

 Quidel Corporation (QDEL) EPS Estimated At $0.45
Investors sentiment decreased to 1.2 in Q3 2017. Its down 1.21, from 2.41 in 2017Q2. It is negative, as 24 investors sold Quidel Corporation shares while 32 reduced holdings. 33 funds opened positions while 34 raised stakes. 30.68 million shares or 6.86% more from 28.71 million shares in 2017Q2 were reported.
The Maryland-based Brown Capital Mgmt Limited Liability Corp has invested 3.06% in Quidel Corporation (NASDAQ:QDEL). Prelude Capital Mngmt Lc holds 0.02% or 4,485 shares in its portfolio. Parametric Portfolio Assocs Lc reported 0% in Quidel Corporation (NASDAQ:QDEL). Morgan Stanley has invested 0% in Quidel Corporation (NASDAQ:QDEL). Driehaus Management Ltd Liability Corporation reported 26,997 shares. Amer International Gp Incorporated accumulated 18,605 shares or 0% of the stock. State Street reported 0% in Quidel Corporation (NASDAQ:QDEL). 35,015 were reported by Credit Suisse Ag. Castleark accumulated 84,518 shares. Sei Invests Comm owns 39,140 shares for 0.01% of their portfolio. California State Teachers Retirement System holds 0% in Quidel Corporation (NASDAQ:QDEL) or 44,429 shares. Barclays Public Lc reported 6,047 shares or 0% of all its holdings. Tig Lc invested in 397,770 shares or 0.98% of the stock. Metropolitan Life New York reported 19,607 shares. Acadian Asset Management Limited Liability Company holds 42,339 shares.

Since August 29, 2017, it had 0 insider buys, and 8 selling transactions for $12.34 million activity. 110,704 shares were sold by Bujarski Robert Joseph, worth $4.40 million. 36,000 shares were sold by BRYANT DOUGLAS C, worth $1.50M. SCHULER JACK W sold $188,080 worth of stock. STEWARD RANDALL J sold $1.46M worth of stock. On Wednesday, January 3 the insider BORKAR RATAN S sold $1.35M.

Analysts expect Quidel Corporation (NASDAQ:QDEL) to report $0.45 EPS on February, 14.They anticipate $0.35 EPS change or 350.00 % from last quarter’s $0.1 EPS. QDEL’s profit would be $15.29M giving it 26.07 P/E if the $0.45 EPS is correct. After having $-0.16 EPS previously, Quidel Corporation’s analysts see -381.25 % EPS growth. The stock increased 0.99% or $0.46 during the last trading session, reaching $46.93. About 288,197 shares traded. Quidel Corporation (NASDAQ:QDEL) has risen 56.78% since January 20, 2017 and is uptrending. It has outperformed by 40.08% the S&P500.

Quidel Corporation (NASDAQ:QDEL) Ratings Coverage

Among 9 analysts covering Quidel (NASDAQ:QDEL), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Quidel had 29 analyst reports since September 2, 2015 according to SRatingsIntel. Canaccord Genuity downgraded the shares of QDEL in report on Tuesday, February 9 to “Hold” rating. The stock of Quidel Corporation (NASDAQ:QDEL) earned “Overweight” rating by PiperJaffray on Tuesday, September 19. The firm has “Buy” rating given on Tuesday, January 2 by Canaccord Genuity. The stock has “Outperform” rating by Raymond James on Monday, June 13. The firm earned “Overweight” rating on Tuesday, September 19 by Barclays Capital. The stock of Quidel Corporation (NASDAQ:QDEL) earned “Buy” rating by Canaccord Genuity on Tuesday, September 19. On Tuesday, July 18 the stock rating was upgraded by Canaccord Genuity to “Buy”. The firm earned “Outperform” rating on Thursday, July 27 by Raymond James. The rating was initiated by CL King on Friday, February 17 with “Neutral”. The rating was maintained by Barclays Capital on Thursday, July 27 with “Overweight”.

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, POC women??s and general health, and gastrointestinal diseases. The company has market cap of $1.60 billion. The firm offers Sofia influenza A+B and QuickVue influenza tests to detect viral antigens of influenza type A and B; Sofia strep A fluorescent immunoassay and QuickVue Strep A tests to detect group A Streptococcal antigen from throat swabs; and Sofia Respiratory Syncytial Virus , QuickVue RSV, and Quidel Molecular RSV + human metapneumovirus tests for respiratory syncytial virus. It currently has negative earnings. It also provides various products to detect various herpes simplex virus (HSV) and herpes family viruses; H&V-Mix to isolate HSV, VZV, and Cytomegalovirus; R-Mix to detect Influenza A and B, RSV, Adenovirus, and Parainfluenza types 1, 2, and 3; Sofia S.

More notable recent Quidel Corporation (NASDAQ:QDEL) news were published by: Marketwatch.com which released: “Quidel Corp.” on December 21, 2009, also Fool.com with their article: “Why Quidel Corporation Is Sinking” published on November 27, 2017, Businesswire.com published: “Quidel Announces Early Termination of the Hart-Scott-Rodino Waiting Period for …” on September 28, 2017. More interesting news about Quidel Corporation (NASDAQ:QDEL) were released by: Businesswire.com and their article: “Quidel Announces Definitive Agreement to Acquire Alere Triage” published on July 17, 2017 as well as Seekingalpha.com‘s news article titled: “Quidel To Acquire Triage Assets From Alere Divestiture” with publication date: July 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.